biotech · Oculopharyngeal Muscular Dystrophy · Head and Neck Squamous Cell Carcinoma · BNTC
Benitec Biopharma
Benitec Biopharma is a biotech organization headquartered in Hayward, USA. It trades on NYSE under ticker BNTC. Primary therapeutic focus areas include Oculopharyngeal Muscular Dystrophy, Head and Neck Squamous Cell Carc
Hayward, USA HQ
2001 Founded
27 Employees
Public company Type
BNTC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Hayward, USA
- Founded
- 2001
- Employees
- 27
- Programs
- 2
- Drugs
- 3
- Patents
- 13
BB-301: Dose escalation phase 1b cohort 1
Phase 2 · gene therapy · Oculopharyngeal Muscular Dystrophy
BB-301: Dose escalation phase 1b cohort 1 for Oculopharyngeal Muscular Dystrophy is a Phase 2 program (gene_therapy) at Benitec Biopharma with 1 ClinicalTrials.gov record(s).
Internal code BNTC-OPMD-BB-301-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Benitec Biopharma
- Phase
- Phase 2
- Modality
- gene_therapy
- Indication
- Oculopharyngeal Muscular Dystrophy
- Status
- active
- Trials
- 1